Simpluris Announces Proposed Settlement involving purchasers of Ampio Pharmaceuticals, Inc.'s ("Ampio") Common Stock

COSTA MESA, Calif. , Oct. 23, 2024 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc.

, court-appointed settlement administrator, regarding the proposed settlement in Wang, et al., v. Ampio Pharmaceuticals, Inc.

, et al., Case No. 1:22-cv-02105-WJM-MEH (D.

Colo.). To: All Persons who purchased or otherwise acquired Ampio Pharmaceuticals, Inc.

's ("Ampio") common stock between December 29, 2020 , and August 2, 2022 , inclusive, and who suffered damages thereby ("Settlement Class"). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Colorado , that Tao Wang and SynWorld Technologies Corporation, Lead Plaintiffs in the Action ("Lead Plaintiffs"), on behalf of themselves and all members of the Settlement Class and Defendants Ampio Pharmaceuticals, Inc. ("Ampio"), Michael A.

Martino , Holli Cherevka , Dan Stokely , David Bar-Or, Philip H. Coelho , and Richard B. Giles (the "Defendants," and collectively with Lead Plaintiffs, the "Parties"), have reached a proposed settlement of the claims in the Action in the amount of $3,000,000 (the "Settlement").

A hearing will be held before the Honorable William J. Martinez , on February 19, 2025 , at 10:30 a.m.

in Courtroom A801 of the United States District Court for the District of Colorado , at the Alfred A. Arraj Courthouse, 901 19th Street, Denver, CO 80294 (the "Settlement Hearing") to, among other things, determi.